Although there are several targets involved here, some of them are worth more attention as potential targets for AD therapeutics: 1) Increased expression of TLRs, diminished endothelial cells, 2) downregulation of VEGF-s, and 3) increase levels of DAMs (Da Mesquita and Kipnis, 2017; Mijit et al., 2020). This evidence concerns the gene VEGFA and Alzheimer disease.